Search

Cetuximab

[A227963] Approved by the FDA in February 2004 under the brand name ERBITUX, cetuximab is used for the treatment of head and neck cancer and metastatic, KRAS wild-type colorectal cancer, and metastatic

Retapamulin

It was approved by the FDA in April 2007.

Flibanserin

In December of 2025 the FDA expanded the age of the indication to include postmenopausal women, a first for the FDA and sexual health in that age group. [L54893] … Flibanserin is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015.

Nelipepimut-S

Isoeugenol

Isoeugenol is a commonly used fragrance added to many commercially available products, and occurs naturally in the essential oils of plants such as ylang-ylang. It is also a significant dermatologic sensitizer and allergen, and as a resu...

Acetrizoic acid

[L1704] Acetrizoic acid presents, in the FDA records, a category of drug substance with an inactive status.[L1703] … [A32135] It was first synthesized by Wallingford in 1953[A32136] and it was filled in the FDA by the Johnson & Johnson subsidiary, Cilag Chemie AG, on February 8th, 1978.

Gavestinel

Gavestinel displays > 1000-fold selectivity over NMDA, AMPA and kainate binding sites and is orally bioavailable and active in vivo.

Zenocutuzumab

[L56179] This approval was expedited following receipt of an FDA Commissioner’s National Priority Voucher. … [L51983] In May 2026, zenocutuzumab was granted additional approval by the US FDA for use in NRG1-positive cholangiocarcinoma.

Teglarinad chloride

Although the exact mechanism of action has yet to be fully elucidated, GMX1778 appears to antagonize nuclear factor-kappa B (NF-kB) transcription, resulting in the induction of tumor cell apoptosis.

Pazopanib

It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.